drugset / Trial / NCT06361823

Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment

NCT06361823

Phase 3 Unknown 74 enrolled Capital Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to investigate the safety and efficacy of semaglutide in patients with Idiopathic intracranial hypertension.

Timeline

Start
2024-05-01
Primary completion
2024-12-01
Completion
2025-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 1 mg Subcutaneous

Indications